Last reviewed 2026-04-20 · How we verify

Cinarin (CYNARINE)

Phase 2 active Small molecule Quality 33/100

Cinarin (generic name: CYNARINE) is a cynarine drug. It is currently in Phase 2 development.

Cinarin works by interacting with specific biological pathways to produce its therapeutic effects.

Cinarin, also known as CYNARINE, is a small molecule drug in the cynarine class. Its original development is unclear, and it is currently owned by an unknown entity. The target and approved indications of Cinarin are unknown, and its commercial status is also unclear. Cinarin has a half-life of 1.37 hours, but its bioavailability and off-patent status are unknown. Further research is needed to understand the full scope of Cinarin's properties and uses.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CYNARINE
Drug class	cynarine
Target	Integrase
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body has a 'volume control' for certain sounds or signals. Cinarin helps adjust this volume control, allowing the right amount of signal to pass through and reducing unwanted noise. This can help with various conditions, but the exact mechanism is still being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cinarin CI brief — competitive landscape report
Cinarin updates RSS · CI watch RSS

Frequently asked questions about Cinarin

What is Cinarin?

Cinarin (CYNARINE) is a cynarine drug.

How does Cinarin work?

Cinarin works by interacting with specific biological pathways to produce its therapeutic effects.

What is the generic name of Cinarin?

CYNARINE is the generic (nonproprietary) name of Cinarin.

What drug class is Cinarin in?

Cinarin belongs to the cynarine class. See all cynarine drugs at /class/cynarine.

What development phase is Cinarin in?

Cinarin is in Phase 2.

What does Cinarin target?

Cinarin targets Integrase and is a cynarine.

Drug class: All cynarine drugs
Target: All drugs targeting Integrase
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing